【摘 要】
：
In the current era of immunotherapy, the treatment of hepatobiliary cancers is rapidly evolving. The use of immunotherapeutic approaches, which include peptide-
【机 构】
：
Department of Hepatobiliary and General Surgery,Humanitas Clinical and Research Center-IRCCS,Rozzano
论文部分内容阅读
In the current era of immunotherapy, the treatment of hepatobiliary cancers is rapidly evolving. The use of immunotherapeutic approaches, which include peptide-based vaccines, checkpoint inhibitors and antibodies, particularly applies to advanced hepatobiliary cancers, for which the availability of limited therapeutic options encourages the adoption of alteative strategies. Thanks to the published/presented, although conflicting, results of some of the clinical trials on this topic together with the incoming results of some other trials, clinicians involved in the cure of hepatobiliary cancer patients need to understand the basic and advanced applications of immunotherapies (1-6).
其他文献
Hepatic resection together with perioperative chemotherapy is currently the only treatment option that can offer a chance of long-term outcome in patients with
An increasing number of patients with colorectal cancer (CRC) are presenting with synchronous disease to the liver. The optimal surgical approach for this compl
IntroductionThe prevalence of obesity has increased over the last decades reaching epidemic proportions: 39% of adults were overweight or obese in 2016 worldwid
In their Letter to the Editor, Wei et al. address on the role of spleen stiffness measurement (SSM) for predicting the late recurrence (＞24 months post-surgery)